MX2021000256A - Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo. - Google Patents

Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.

Info

Publication number
MX2021000256A
MX2021000256A MX2021000256A MX2021000256A MX2021000256A MX 2021000256 A MX2021000256 A MX 2021000256A MX 2021000256 A MX2021000256 A MX 2021000256A MX 2021000256 A MX2021000256 A MX 2021000256A MX 2021000256 A MX2021000256 A MX 2021000256A
Authority
MX
Mexico
Prior art keywords
coagulation factor
factor xia
preparing
xia inhibitor
preparing coagulation
Prior art date
Application number
MX2021000256A
Other languages
English (en)
Inventor
Yong Wang
Feng He
Zhongjun Guan
Jian Huang
Jun Feng
Zhuoxun Xi
Yingqiang Feng
Yanli Mao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021000256A publication Critical patent/MX2021000256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención involucra un método para preparar un inhibidor del factor de coagulación XIa y un intermediario del mismo. Específicamente, la presente invención involucra un método para preparar un derivado de oxipiridina amida. El método tiene las ventajas de alto rendimiento, buena pureza del producto y condiciones de reacción suaves.
MX2021000256A 2018-07-19 2019-07-18 Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo. MX2021000256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810796646 2018-07-19
PCT/CN2019/096504 WO2020015698A1 (zh) 2018-07-19 2019-07-18 一种凝血因子XIa抑制剂及其中间体的制备方法

Publications (1)

Publication Number Publication Date
MX2021000256A true MX2021000256A (es) 2021-03-25

Family

ID=69163576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000256A MX2021000256A (es) 2018-07-19 2019-07-18 Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.

Country Status (12)

Country Link
US (1) US20210292279A1 (es)
EP (1) EP3825311A4 (es)
JP (1) JP2021530497A (es)
KR (1) KR20210033953A (es)
CN (1) CN111094268B (es)
AU (1) AU2019304392A1 (es)
BR (1) BR112021000439A2 (es)
CA (1) CA3106120A1 (es)
MX (1) MX2021000256A (es)
TW (1) TW202019904A (es)
WO (1) WO2020015698A1 (es)
ZA (1) ZA202007755B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225462B2 (en) * 2018-07-02 2022-01-18 Jiangsu Hengrui Medicine Co., Ltd. Crystal forms of oxypyridine amide derivative and preparation method therefor
CN112010774B (zh) * 2019-05-28 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
CN1944398A (zh) * 2005-01-11 2007-04-11 中国医学科学院药物研究所 新的苯甲酰胺类化合物及其制法和药物用途
FR3005160B1 (fr) * 2013-04-29 2016-02-12 Sagem Defense Securite Capteur angulaire inertiel de type mems equilibre et procede d'equilibrage d'un tel capteur
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US20190119213A1 (en) * 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
MX2018001447A (es) * 2015-08-03 2019-02-21 Harvard College Bloqueadores de canal de ion cargado y metodos para su uso.
JP6785838B2 (ja) * 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
WO2017037051A1 (de) * 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN107033043B (zh) * 2016-02-04 2019-04-30 中国人民解放军第二军医大学 N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
TWI592671B (zh) * 2016-08-04 2017-07-21 台達電子工業股份有限公司 絕緣偵測電路、電源轉換裝置及絕緣阻抗值偵測方法
RU2742771C2 (ru) 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное оксопиколинамида, способ его получения и его фармацевтическое применение
CN107793396B (zh) * 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
AU2017348183A1 (en) * 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR

Also Published As

Publication number Publication date
CN111094268A (zh) 2020-05-01
CA3106120A1 (en) 2020-01-23
AU2019304392A1 (en) 2021-01-28
EP3825311A1 (en) 2021-05-26
BR112021000439A2 (pt) 2021-04-06
JP2021530497A (ja) 2021-11-11
EP3825311A4 (en) 2022-08-31
KR20210033953A (ko) 2021-03-29
TW202019904A (zh) 2020-06-01
CN111094268B (zh) 2022-07-26
WO2020015698A1 (zh) 2020-01-23
ZA202007755B (en) 2022-06-29
US20210292279A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2022001829A (es) Proceso de fabricación de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
MY195408A (en) Novel Aspartokinase Variant and Method for Producing L- Amino Acid Using the Same
SG10201902609TA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MX2019006715A (es) Metodo de preparacion de compuestos triciclicos.
EP3778901A4 (en) NEW PROMOTER AND PROCESS FOR THE PRODUCTION OF L-AMINO ACID USING THE PROMOTER
ZA202306226B (en) Sulfone derivative production method
MX2021000256A (es) Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
MX2018009493A (es) Uso combinado de al menos una endoproteasa y al menos una exoproteasa en un proceso simultaneo de sacarificacion y fermentacion (ssf) para mejorar la produccion de etanol.
MX2022005229A (es) Un nuevo proceso eficaz para la sintesis de 2-amino-5-cloro-n,3-di metilbenzamida.
MX2020007646A (es) Procesos para la sintesis de sulfentrazona.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
WO2018144607A8 (en) Apparatus and continuous flow process for production of boronic acid derivative
MY197949A (en) Process for pd-catalyzed hydroxycarbonylation of diisobutene: acetic acid/diisobutene ratio
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
JOP20220021A1 (ar) تخليق على مقياس العملية لمثبط كاليكرين في البلازما
MX2020004034A (es) Metodo de preparacion para un inhibidor de tirosina cinasa e intermediario del mismo.
EP3941911A4 (en) METHOD FOR THE SYNTHESIS OF 2,5-FURANDICARBOXYLIC ACID
EP4249491A3 (en) Process for preparing bicyclic enolether
MX2021011548A (es) Proceso novedoso para la preparacion de filgotinib e intermediarios del mismo.
PH12019500484A1 (en) Optimized production method for pest control agent
MX2019000984A (es) Proceso para preparacion de indanonas.
MX2022006856A (es) Proceso e intermediarios para la produccion de formula (i).
MX2022006044A (es) Proceso para preparar analogos de araquidonoiletanolamina.
MX2022005422A (es) Procedimiento para la preparacion de compuestos organicos ferricos.
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.